CD4-mediated signals induce T cell dysfunction in vivo

Area of Science:

• Immunology
• Molecular Biology
• Cellular Signaling

Background:

• CD4 coreceptors can suppress T cell receptor (TCR)/CD3-induced interleukin-2 (IL-2) secretion in human and murine T cells.
• Understanding the precise mechanisms of CD4-mediated regulation of T cell activation is crucial for developing targeted immunotherapies.

Purpose of the Study:

• To investigate how CD4-specific monoclonal antibodies (mAbs) affect T cell activation pathways, specifically the IL-2 promoter factors NF-AT and AP-1.
• To elucidate the role of CD4 ligation in the activation of extracellular signal-regulated kinase (Erk) 2 and c-Jun N-terminal kinase (JNK) signaling.
• To determine the in vivo relevance of anti-CD4 mAb effects on T cell proliferation, IL-2 secretion, and cytokine profiles, and the impact of CD28 costimulation.

Main Methods:

• Pretreatment of murine CD4+ T cells with anti-CD4 mAb (YTS177) followed by stimulation with anti-TCR/CD3.
• Analysis of NF-AT and AP-1 activation, and Erk2 and JNK kinase activity.
• In vivo studies using BALB/c mice injected with anti-CD4 mAb, assessing T cell proliferation, IL-2, and IL-4 secretion in response to OVA antigen and anti-CD28 mAb.

Main Results:

• Anti-CD4 mAb inhibited CD3-mediated activation of NF-AT and AP-1, and impaired anti-CD3-induced Erk2 activation.
• CD28 costimulation overcame anti-CD4 inhibition by inducing JNK activation.
• In vivo, anti-CD4 mAb inhibited OVA-induced T cell proliferation and IL-2 secretion, but CD28 costimulation restored IL-2 secretion and enhanced IL-4 secretion.

Conclusions:

• CD4-specific antibodies inhibit T cell activation via TCR signaling but potentiate CD28-mediated costimulation.
• These findings provide insights into the mechanisms of tolerance induced by nondepleting anti-CD4 mAbs.
• The results have implications for understanding and developing immunosuppressive therapies for allograft rejection and autoimmune diseases.